Panacea Biotec to make 100 mn doses of Sputnik V for global markets

More players like Serum Institute expected to join the fray to make Sputnik V

As India emerges as a major manufacturing hub for the Russian vaccine Sputnik V, the latest firm to partner with Russian Direct Investment Fund (RDIF) to make the Sputnik V vaccine in India is Panacea Biotec that will make 100 million doses of the vaccine here annually for the global market.

With this the total manufacturing capacity of Sputnik V in India becomes 852 million doses annually from partners including Stelis Pharma (Strides arm), Hetero, Gland Pharma, Virchow Group. More players are likely to sign manufacturing agreements with RDIF soon, claimed sources.

Apart from Panacea Biotec, even Serum Institute of India is